Modelling light-dark regime influence on the carbon-nitrogen metabolism in a unicellular diazotrophic cyanobacterium

International audienceWe propose a dynamical model depicting nitrogen (N2 ) fixation (diazotrophy) in a unicellular cyanobacterium, Crocosphaera watsonii, grown under light limitation and obligate diazotrophy. In this model, intracellular carbon and nitrogen are both divided into a functional pool and a storage pool. An internal pool that explicitly describes the nitrogenase enzyme is also added. The model is successfully validated with continuous culture experiments of C. watsonii under three light regimes, indicating that proposed mechanisms accurately reproduce the growth dynamics of this organism under various light environments. Then, a series of model simulations is run for a range of light regimes with different photoperiods and daily light doses. Results reveal how nitrogen and carbon are coupled, through the diel cycle, with nitrogenase dynamics, whose activity is constrained by the light regime. We finally identify optimal productivity conditions

Programmes and calls for public health research in European countries

Introduction: Public health research, at population and organizational level, needs to be identified independently within 'health' research from biomedicine and life sciences. In PHIRE (Public Health Innovation and Research in Europe), we investigated the extent and character of public health research calls and programmes in European countries. METHODS: Country respondents, identified through national member associations of the European Public Health Association completed a standardized recording instrument. Public health research was defined, and the call period limited to the latest full year (2010). Of the 30 countries included (EU 27 plus Iceland, Norway and Switzerland), there were reports for 25 countries A simple classification of the calls was developed. RESULTS: There were 75 calls and programmes included. Of these, 41 (55%) together were in France and the UK, and 34 in a further 14 countries, while 9 countries reported there were no calls or programmes opened in 2010. Calls were categorized across diseases, behaviours, determinants, services and methodologies. Some calls were broad, while others-particularly in the countries with several calls-were more detailed towards specific issues. Levels of funding varied markedly and were difficult to define. Where stated, in 32 responses, 19 calls were only open to national applicants and 13 from abroad. CONCLUSIONS: Most European countries have competitive programmes and calls relevant for public health research, but they are poorly identified. Only a minority of countries present a wide range of topics and specific fields. Effort is needed to develop classifications for public health programmes and calls for public health research, improve information (including financial) collection to enable systematic comparisons and build greater recognition of public health research within research communities, with national and European research funding organizations, and for practitioners and policymakers.PHIRE received co-funding from the European Union Health Programme, agreement no. 2009 12 14

Modelling the effect of temperature on phytoplankton growth across the global ocean

International audiencePhytoplankton are ectotherms and are thus directly influenced by temperature. They experience temporal variation in temperature which results in a selection pressure. Using the Adaptive Dynamics theory and an optimization method, we study phytoplankton thermal adaptation (more particulary the evolution of the optimal growth temperature) to temperature fluctuations. We use this method at the scale of global ocean and compare two existing models. We validate our approach by comparing model predictions with experimental data sets from 57 species. Finally, we show that temperature actually drives evolution and that the optimum temperature for phytoplankton growth is strongly linked to thermal amplitude variations

High-resolution imaging of the Pyrenees and Massif Central from the data of the PYROPE and IBERARRAY portable array deployments

International audienceThe lithospheric structures beneath the Pyrenees, which holds the key to settle long-standing controversies regarding the opening of the Bay of Biscay and the formation of the Pyrenees, are still poorly known. The temporary PYROPE and IBERARRAY experiments have recently filled a strong deficit of seismological stations in this part of western Europe, offering a new and unique opportunity to image crustal and mantle structures with unprecedented resolution. Here we report the results of the first tomographic study of the Pyrenees relying on this rich data set. The important aspects of our tomographic study are the precision of both absolute and relative traveltime measurements obtained by a nonlinear simulated annealing waveform fit and the detailed crustal model that has been constructed to compute accurate crustal corrections. Beneath the Massif Central, the most prominent feature is a widespread slow anomaly that reflects a strong thermal anomaly resulting from the thinning of the lithosphere and upwelling of the asthenosphere. Our tomographic images clearly exclude scenarios involving subduction of oceanic lithosphere beneath the Pyrenees. In contrast, they reveal the segmentation of lithospheric structures, mainly by two major lithospheric faults, the Toulouse fault in the central Pyrenees and the Pamplona fault in the western Pyrenees. These inherited Hercynian faults were reactivated during the Cretaceous rifting of the Aquitaine and Iberian margins and during the Cenozoic Alpine convergence. Therefore, the Pyrenees can be seen as resulting from the tectonic inversion of a segmented continental rift that was buried by subduction beneath the European plate

Impact of social ties on self reported health in France: Is everyone affected equally?

<p>Abstract</p> <p>Aim</p> <p>To examine the association of social ties and income with self reported health, in order to investigate if social ties have a greater impact on the health of people on low incomes compared to those financially better off.</p> <p>Methods</p> <p>A nationally representative cross-sectional study of 5205 French adults using data from questionnaires which asked about health, income and relationships with family and friends etc.</p> <p>Results</p> <p>Less than good self-rated health (SRH) is twice as frequently reported by people in the lowest income group than those in the highest income group. People with low incomes are also more likely to have felt alone on the previous day, received no phone call during the last week, have no friends, not be a member of a club, and to live alone. Socially isolated people report lower SRH. Likelihood ratio tests for interaction vs. main effect models were statistically significant for 2 of the measures of social ties, borderline for 2 others and non-significant for one. For 4 of the 5 indicators of social ties, larger odd ratios show that social isolation is more strongly associated with less than good SRH among people on low incomes compared to those with a higher income.</p> <p>Conclusion</p> <p>Social isolation is associated with 'less than good' self-rated health. This effect appears to be more important for people on a low income.</p

Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting.

Abstract Background Though the Expanded Disability Status Scale (EDSS) is commonly used to assess disability level in relapsing-remitting multiple sclerosis (RRMS), the criteria defining disability progression are used for patients with a wide range of baseline levels of disability in relatively short-term trials. As a result, not all EDSS changes carry the same weight in terms of future disability, and treatment benefits such as decreased risk of reaching particular disability milestones may not be reliably captured. The objectives of this analysis are to assess the probability of confirmed disability worsening to specific EDSS milestones (i.e., EDSS scores ≥3.0, ≥4.0, or ≥6.0) at 288 weeks in the Tysabri Observational Program (TOP) and to examine the impact of relapses occurring during natalizumab therapy in TOP patients who had received natalizumab for ≥24 months. Methods TOP is an ongoing, open-label, observational, prospective study of patients with RRMS in clinical practice. Enrolled patients were naive to natalizumab at treatment initiation or had received ≤3 doses at the time of enrollment. Intravenous natalizumab (300 mg) infusions were given every 4 weeks, and the EDSS was assessed at baseline and every 24 weeks during treatment. Results Of the 4161 patients enrolled in TOP with follow-up of at least 24 months, 3253 patients with available baseline EDSS scores had continued natalizumab treatment and 908 had discontinued (5.4% due to a reported lack of efficacy and 16.4% for other reasons) at the 24-month time point. Those who discontinued due to lack of efficacy had higher baseline EDSS scores (median 4.5 vs. 3.5), higher on-treatment relapse rates (0.82 vs. 0.23), and higher cumulative probabilities of EDSS worsening (16% vs. 9%) at 24 months than those completing therapy. Among 24-month completers, after approximately 5.5 years of natalizumab treatment, the cumulative probabilities of confirmed EDSS worsening by 1.0 and 2.0 points were 18.5% and 7.9%, respectively (24-week confirmation), and 13.5% and 5.3%, respectively (48-week confirmation). The risks of 24- and 48-week confirmed EDSS worsening were significantly higher in patients with on-treatment relapses than in those without relapses. An analysis of time to specific EDSS milestones showed that the probabilities of 48-week confirmed transition from EDSS scores of 0.0–2.0 to ≥3.0, 2.0–3.0 to ≥4.0, and 4.0–5.0 to ≥6.0 at week 288 in TOP were 11.1%, 11.8%, and 9.5%, respectively, with lower probabilities observed among patients without on-treatment relapses (8.1%, 8.4%, and 5.7%, respectively). Conclusions In TOP patients with a median (range) baseline EDSS score of 3.5 (0.0–9.5) who completed 24 months of natalizumab treatment, the rate of 48-week confirmed disability worsening events was below 15%; after approximately 5.5 years of natalizumab treatment, 86.5% and 94.7% of patients did not have EDSS score increases of ≥1.0 or ≥2.0 points, respectively. The presence of relapses was associated with higher rates of overall disability worsening. These results were confirmed by assessing transition to EDSS milestones. Lower rates of overall 48-week confirmed EDSS worsening and of transitioning from EDSS score 4.0–5.0 to ≥6.0 in the absence of relapses suggest that relapses remain a significant driver of disability worsening and that on-treatment relapses in natalizumab-treated patients are of prognostic importance

DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France

We evaluated the effect of DMTs on Covid-19 severity in patients with MS, with a pooled-analysis of two large cohorts from Italy and France. The association of baseline characteristics and DMTs with Covid-19 severity was assessed by multivariate ordinal-logistic models and pooled by a fixed-effect meta-analysis. 1066 patients with MS from Italy and 721 from France were included. In the multivariate model, anti-CD20 therapies were significantly associated (OR&nbsp;=&nbsp;2.05, 95%CI&nbsp;=&nbsp;1.39–3.02, p&nbsp;&lt;&nbsp;0.001) with Covid-19 severity, whereas interferon indicated a decreased risk (OR&nbsp;=&nbsp;0.42, 95%CI&nbsp;=&nbsp;0.18–0.99, p&nbsp;=&nbsp;0.047). This pooled-analysis confirms an increased risk of severe Covid-19 in patients on anti-CD20 therapies and supports the protective role of interferon